(RTTNews.com) - Lupin Limited and AbbVie Inc. (ABBV) said that AbbVie has licensed Lupin's MALT1 or Mucosa-Associated Lymphoid Tissue Lymphoma Translocation Protein 1 inhibitor program.
Under the partnership, AbbVie gains exclusive global rights to develop and commercialize Lupin's MALT1 inhibitors. MALT-1 is a protein involved in T-cell and B-cell lymphocyte activation and AbbVie intends to pursue development across a range of hematological cancers, many with limited current treatment options.
As per the terms of the agreement, AbbVie will pay Lupin an upfront payment of US$30 million for an exclusive license to the program. Upon successful completion of regulatory, development and commercial milestones, Lupin is eligible to receive total milestone payments of up to US$947 million.
Additionally, Lupin will be entitled to receive a double-digit royalty on the sales of the product and will retain commercial rights to the program in India.
Read the original article on RTTNews (http://www.rttnews.com/2965248/lupin-abbvie-to-develop-novel-oncology-drug-to-treat-hematological-cancers.aspx)
For comments and feedback: contact email@example.com
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.